Application of cAMP-dependent catalytic subunit β (PRKACB) Low Expression in Predicting Worse Overall Survival: A Potential Therapeutic Target for Colorectal Carcinoma

Xiaoya Yao; Weixian Hu; Jie Zhang; Chengzhi Huang; Haibi Zhao; Xueqing Yao

doi:10.7150/jca.46156

Application of cAMP-dependent catalytic subunit β (PRKACB) Low Expression in Predicting Worse Overall Survival: A Potential Therapeutic Target for Colorectal Carcinoma

J Cancer. 2020 Jun 7;11(16):4841-4850. doi: 10.7150/jca.46156. eCollection 2020.

Authors

Xiaoya Yao^{1

2}, Weixian Hu^{3

2}, Jie Zhang^{3

2}, Chengzhi Huang^{2

4}, Haibi Zhao^{1

2}, Xueqing Yao^{2

3

4

1

5}

Affiliations

¹ School of Bioscience and Bioengineering, South China University of Technology, Guangzhou, Guangdong, People's Republic of China.
² Department of General Surgery, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, People's Republic of China.
³ The Second School of Clinical Medicine, Southern Medical University, Guangzhou, People's Republic of China.
⁴ School of Medicine, South China University of Technology, Guangzhou, Guangdong, People's Republic of China.
⁵ Shantou University Medical College, Shantou, Guangdong, People's Republic of China.

Abstract

Low expressions of PRKACB are related to the occurrence of various human malignancies. However, the prognostic value of PRKACB expression in colorectal cancer (CRC) patients remains controversial. In this analysis, PRKACB expression in CRC tumors was evaluated across the GEO, TCGA, and Oncomine databases, and a PRKACB survival analysis was performed based on the TCGA profile. We detected PRKACB in 7 GEO series (GSE110225, GSE32323, GSE44076, GSE9348, GSE41328, GSE21510, GSE68468) and TCGA spectra (all P <0.05). A meta-analysis performed in the Oncomine database revealed that PRKACB was significantly up-regulated in neoplastic tissues compared to normal tissues (all P <0.05). A Kaplan-Meier analysis demonstrated that lower PRKACB expression in tumors was significantly associated with poorer overall survival (OS) in patients with CRC (P <0.05). A subgroup analysis showed that low expression of PRKACB correlated with poor 1-, 3-, and 5-year OS (all P <0.05). Furthermore, in males (P = 0.0083), whites (P = 0.0463), and non-mucinous adenocarcinoma patients (P = 0.0108), the down-regulation of PRKACB expression was more significant for the OS prognostic value. Conclusion: PRKACB is down-regulated in tumors and associated with worsening OS in CRC patients.

Keywords: PRKACB; colorectal carcinoma; survival; therapeutic target.